Medistim ASA (DE:MD1) has released an update.
Medistim ASA, a leader in ultrasound technology, has completed its Early Access program for the new MiraQ™ INTUI software platform, aiming for a December launch. With devices already used in a significant portion of coronary artery bypass procedures globally, the company sees growth opportunities, particularly in the U.S. market. The INTUI platform promises to enhance surgical efficiency and patient outcomes, with plans to expand into vascular applications.
For further insights into DE:MD1 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- 23andMe Cuts 40% Staff, Shutters Drug Development Ahead of Q2 Print
- Tesla Option Contracts Gain on Post-Election Rally, Pushing Shares up 9%
- ‘Patience Running Out,’ Says Bernstein About Ford Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
